Classical cardiovascular disease risk factors associate with vascular function and morphology in rheumatoid arthritis: a six-year prospective study by Aamer Sandoo et al.
Sandoo et al. Arthritis Research & Therapy 2013, 15:R203
http://arthritis-research.com/content/15/6/R203RESEARCH ARTICLE Open AccessClassical cardiovascular disease risk factors
associate with vascular function and morphology
in rheumatoid arthritis: a six-year prospective study
Aamer Sandoo1,2*, Neil Chanchlani1, James Hodson3, Jacqueline P Smith1, Karen M Douglas1
and George D Kitas1,2,4Abstract
Introduction: Patients with rheumatoid arthritis (RA) are at an increased risk for cardiovascular disease (CVD). An
early manifestation of CVD is endothelial dysfunction which can lead to functional and morphological vascular
abnormalities. Classical CVD risk factors and inflammation are both implicated in causing endothelial dysfunction in
RA. The objective of the present study was to examine the effect of baseline inflammation, cumulative
inflammation, and classical CVD risk factors on the vasculature following a six-year follow-up period.
Methods: A total of 201 RA patients (155 females, median age (25th to 75th percentile): 61 years (53 to 67)) were
examined at baseline (2006) for presence of classical CVD risk factors and determination of inflammation using
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). At follow-up (2012) patients underwent assessments
of microvascular and macrovascular endothelium-dependent and endothelium-independent function, along with
assessment of carotid atherosclerosis. The CRP and ESR were recorded from the baseline study visit to the follow-up
visit for each patient to calculate cumulative inflammatory burden.
Results: Classical CVD risk factors, but not RA disease-related inflammation, predicted microvascular
endothelium-dependent and endothelium-independent function, macrovascular endothelium-independent
function and carotid atherosclerosis. These findings were similar in a sub-group of patients free from CVD, and
not receiving non-steroidal anti-inflammatory drugs, cyclooxygenase 2 inhibitors or biologics. Cumulative
inflammation was not associated with microvascular and macrovascular endothelial function, but a weak
association was apparent between area under the curve for CRP and carotid atherosclerosis.
Conclusions: Classical CVD risk factors may be better long-term predictors of vascular function and morphology
than systemic disease-related inflammation in patients with RA. Further studies are needed to confirm if
assessments of vascular function and morphology are predictive of long-term CV outcomes in RA.Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory mus-
culoskeletal disease characterised by pain, swelling and
stiffness of the joints [1]. Patients with RA also have an in-
creased risk for cardiovascular disease (CVD) compared to
the general population [2]. It has been hypothesised that
systemic RA-related inflammation exerts deleterious effects* Correspondence: aamer.sandoo@dgh.nhs.uk
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reproduction in any medium, provided the oron classical CVD risk factors and the vasculature [3], most
likely due to similarities between the pathogenesis of RA
and atherosclerosis [4].
The endothelium is the innermost layer of the vascula-
ture and is responsible for maintaining an atheroprotective
environment within the vessel. Damage to the endothe-
lium from injurious stimuli such as oxidative stress and in-
flammatory mediators results in endothelial dysfunction,
primarily through a reduction in the antiatherogenic mol-
ecule nitric oxide (NO) [5]. Several noninvasive assess-
ments of vascular function and morphology can examine
different stages of subclinical atherosclerosis and provide
useful information on an individual’s CVD risk status.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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agonists is commonly used to assess endothelial function
in the microvasculature, whereas flow-mediated dilatation
(FMD) (endothelium-dependent) and glyceryl trinitrate–
mediated dilatation (GTN) (endothelium-independent) are
used to assess macrovascular endothelial function. Assess-
ment of vascular morphology is typically performed using
high-resolution B-mode ultrasonography in the carotid ar-
teries, which provides information on the carotid artery
intima-media thickness (cIMT) [5]. These assessments are
good predictors of future cardiac events in the general
population and in patients with CVD [6,7].
Patients with RA have evidence of impaired vascular
function and morphology compared to healthy age- and
sex-matched controls, but this can be improved by treat-
ment with anti-inflammatory drugs [8]. Despite the benefi-
cial effect of anti-inflammatory drug treatment, however,
associations between systemic inflammation and the vas-
culature is not clearly evident in the literature (which
comprises mainly cross-sectional studies) [8,9]. Owing to
the fluctuating nature of inflammation in RA, it is possible
that assessment of inflammation at a single time point
does not accurately reflect the inflammatory insult to the
vascular wall over a longer period of time. Characterisa-
tion of cumulative inflammation (which incorporates serial
measurements of inflammatory markers) might be a better
indicator of the patient’s overall inflammatory burden and
subsequent risk of developing vascular abnormalities [10].
To the best of our knowledge, investigators in only a
few studies have assessed the impact of cumulative in-
flammation on the vasculature, and they have reported
mixed findings. For example, some studies have found
an association between cumulative inflammation and
the vasculature [11-13], but others have not [14,15].
These contrasting findings are difficult to reconcile, as
most of the studies used different methods to determine
retrospective or cumulative inflammation. Furthermore,
the majority of studies have focused mainly on assess-
ments of vascular morphology, with no study having
examined the impact of cumulative inflammation on
microvascular endothelial function.
The prevalence of classical CVD risk factors such as
hypertension, dyslipidaemia and insulin resistance are
increased in RA [16]. We have previously shown that
classical CVD risk factors, but not RA-related inflamma-
tion, are associated with microvascular and macrovascu-
lar endothelial function in RA [9]. Classical CVD risk
factors also appear to predict the progression of carotid
plaque in patients with RA [17]. It is possible that sys-
temic RA-related inflammation mediates the association
between classical CVD risk factors and the vasculature,
as some studies have reported that systemic inflamma-
tory markers associate only with vascular abnormalities
in the presence of classical CVD risk factors [18].The objective of the present prospective RA cohort
study was to examine the effect of baseline inflammation
and classical CVD risk factors on the vasculature following
a six-year follow-up period. A secondary objective was to
assess associations between cumulative inflammatory bur-
den and the vasculature.Methods
Participants
Four hundred consecutive RA patients were recruited from
the rheumatology outpatient clinics of The Dudley Group
NHS Foundation Trust in the United Kingdom in 2006.
The patients were part of the Dudley Rheumatoid Arthritis
Comorbidity Cohort (DRACCO) study, a prospective study
examining CVD burden in RA. Detailed characteristics of
these patients have been reported previously [19]. Since
the initiation of our present study, 78 patients have died
due to various causes (cardiac and noncardiac). The
remaining 322 were asked to return for a follow-up visit in
2012. From among those patients, 201 agreed to take part
in the follow-up study. Only the baseline data (2006) from
these patients are reported in this article. All patients met
the 1987 revised RA criteria of the American Rheumatism
Association [20]. Our study received ethical approval from
The Black Country Research Ethics Committee. All partici-
pants gave their written informed consent according to the
Declaration of Helsinki.
Protocol for baseline visit
All patients reported to the clinical research facility after a
12-hour overnight fast and underwent a thorough baseline
evaluation, including a detailed review of their medical
history and hospital records, a physical examination and
contemporaneous assessments of height, weight, body
mass index, body composition (using a BC-418 Segmental
Body Composition Analyzer; Tanita Corporation of Amer-
ica, Arlington Heights, IL, USA), current Disease Activity
Score in 28 joints [21] and physical function using the
Health Assessment Questionnaire [22]. The Framingham
and Reynolds risk scores were calculated as previously de-
scribed [9]. All medications and their indications were also
recorded. Venous blood was collected on the same day as
the baseline evaluation, and a wide range of tests were per-
formed. Biochemical and haematological estimations in-
cluded fasting lipids, complete serum biochemistry, fasting
glucose, fasting insulin, C-reactive protein (CRP) and
erythrocyte sedimentation rate (ESR). Insulin resistance
was assessed by calculating the homeostasis model assess-
ment of insulin resistance and the quantitative insulin sen-
sitivity check index as previously described [23,24]. All
biochemical tests were carried out in the Biochemistry
Laboratory at Russells Hall Hospital, The Dudley Group
NHS Foundation Trust, United Kingdom.
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Patients reported to a temperature-controlled vascular la-
boratory (22°C) after a 12-hour overnight fast 6 years after
the baseline assessment. All patients underwent the same
examinations and assessments as in the baseline visit. In
addition, patients underwent several functional and mor-
phological vascular assessments, including LDI with ionto-
phoresis of acetylcholine (ACh) and sodium nitroprusside
(SNP) (microvascular endothelial function) and assess-
ments of FMD and GTN (macrovascular endothelial func-
tion) as well as cIMT (carotid atherosclerosis).
Microvascular endothelial function
Endothelial function of the microvasculature was assessed
noninvasively by a single observer (AS) using LDI
(moorLDI2 SIM; Moor Instruments, Axminster, UK)
with iontophoresis of 1% ACh (Miochol-E 20 mg;
Novartis Pharmaceuticals UK, Horsham, UK) and 1%
SNP (Nitroprussiat; Fides Ecopharma, Madrid, Spain) in
2.5 ml of solution containing 0.5% saline. The technique
was performed according to established guidelines [25]
and has been described in detail previously [5]. Briefly,
after a baseline scan, ten scans were recorded during
iontophoresis of the vasoactive agents using a 30-μA
current, followed by two scans during recovery. This
technique has intraobserver coefficients of variation
(CVs) for ACh and SNP of 6.5% and 5.9%, respectively,
in our laboratory.
Macrovascular endothelial function
Assessment of macrovascular endothelium-dependent
function was performed using FMD with high-resolution
ultrasonography of the brachial artery (ACUSON Antares
Ultrasound System; Siemens Healthcare Diagnostics,
Camberley, UK) according to previously established
guidelines [26]. Endothelium-independent responses
were examined by administration of a 500-μg sublingual
GTN tablet (Alpharma, Barnstaple, UK). The intraob-
server CV for the study ultrasonographer (AS) was
10.7% for FMD assessments and 11.8% for GTN assess-
ments. For all vascular tests, endothelial function was
expressed as the percentage increase in perfusion or diam-
eter from baseline, and all analyses were carried out offline
by AS, who was blinded to the identities of the patients.
Carotid atherosclerosis
High-resolution ultrasonography of the carotid artery was
performed by an experienced ultrasonographer (AS) ac-
cording to previously established guidelines [27] using a
10-MHz linear array probe attached to the same high-
resolution ultrasound scanner used for the FMD assess-
ment. cIMT was defined by determining the thickness be-
tween the lines of Pignoli, with the first echogenic line
representing the lumen-intima interface and the secondline representing the media-adventitia interface [28]. As-
sessments of cIMT were performed in the far wall,
1 cm proximal to the carotid bulb at sites free of
plaque in both the right and left common carotid ar-
teries using the longitudinal scanning plane. Three mea-
surements were taken on each side and averaged to give
the mean IMT for the right and left carotid arteries se-
parately. The IMTs from both sides were further averaged
to give the overall IMT. The intraobserver CV for AS
was 8.6%.
Cumulative inflammatory burden
Detailed information on all inflammatory markers (CRP
and ESR) from the baseline visit to the follow-up visit for
each patient was used to calculate cumulative inflammatory
burden. A quarterly measurement of CRP and ESR for each
year the patient was in the study was used to calculate the
areas under the curve (AUCs) for each parameter.
Statistical analysis
Baseline predictors of vascular outcomes
All statistical analyses were performed using IBM SPSS
version 20 software (IBM SPSS Inc, Chicago, IL, USA).
Initially, six baseline predictors of vascular outcomes were
chosen. These included four prevalent classical CVD risk
factors in RA (hypertension, dyslipidaemia, insulin resist-
ance and diabetes), along with CRP and ESR. The five vas-
cular outcomes were measurements of ACh, SNP, FMD,
GTN and cIMT. In cases where the factor considered
was binary and the outcome was continuous, either a
t-test or Mann–Whitney U test was performed, de-
pending on the distribution of the variable, with the
results summarised as mean (SE) or median (interquartile
range), respectively. In cases where both the variables
were continuous, Spearman’s correlation coefficients were
calculated. Because so many comparisons were made, the
significance of each test was evaluated at both the stan-
dard critical value of P < 0.05, as well as according to
the Bonferroni-corrected version of P < 0.001, to mi-
nimise the chance of false-positives. The analysis was
repeated in a subgroup of patients (n = 104) who were
free of overt CVD and were not taking nonsteroidal
anti-inflammatory drugs (NSAIDs), cyclooxygenase 2
(COX2) inhibitors or anti–tumour necrosis factor α
(anti-TNFα) inhibitors.
Cumulative inflammatory burden and vascular outcomes
The AUCs for the CRP and ESR data were calculated for
the quarterly measurements taken between 2006 and
2012. Because some patients had missing data at the
start or the end of the period, the AUCs were dependent
on the length of time for which data were available. For
this reason, the resulting AUCs were divided by the total
period of data collection for each patient to produce
Table 1 Patient characteristics for all rheumatoid arthritis






Age (years) 61 (53 to 67) 67 (59 to 73)
Female, n (%) 155 (77) 155 (77)
Body mass index (kg/m2) 27 (24 to 30) 28 (24 to 32)
Disease characteristics
Age at RA onset (years) 46 ± 13 –
Disease duration (years) 10 (4 to 18) 16 (11 to 25)
Rheumatoid factor-positive, n (%) 148 (74) 148 (74)
Anti-CCP autoantibody-positive, n (%) 123 (61) 123 (61)
DAS28 score 4.0 (3.1 to 4.8) 3.1 (2.5 to 4.0)
C-reactive protein (mg/L) 7.5 (4.3 to 16) 3 (2.9 to 8.5)
Erythrocyte sedimentation rate (mm/h) 17 (8 to 30) 12 (5 to 23)
HAQ 1.3 ± 0.9 1.6 ± 0.9
Extraarticular manifestations, n (%)b 147 (73) –
Cardiovascular disease risk factors
Hypertension, n (%) 132 (66) 130 (65)
Dyslipidaemia, n (%) 115 (57) 158 (79)
Insulin resistance, n (%) 65 (32) 53 (26)
Diabetes, n (%) 7 (4) 21 (10)
Current smokers 33 (16) 23 (11)
Global cardiovascular disease riskc
Framingham risk score (%) 4.6 ± 5.3 9.2 ± 6.3
Reynolds risk score (%) 6.3 ± 6.4 9.6 ± 8.3
RA medications
Methotrexate, n (%) 128 (64) 122 (61)
Hydroxychloroquine, n (%) 36 (18) 50 (25)
Prednisolone, n (%) 58 (29) 51 (25)
Prednisolone dose (mg) 6 ± 3 7 ± 8
NSAIDs, n (%) 47 (23) 26 (13)
Cyclooxygenase 2 inhibitors, n (%) 14 (7) 5 (2.5)
Anti-TNFα therapy, n (%) 20 (10) 57 (28)
Tociluzimab, n (%) – 3 (1.5)
Cardiovascular medications
Antihypertensives, n (%) 81 (40) 79 (39)
Antihypercholesterolaemics, n (%) 33 (16) 74 (37)
β-blockers, n (%) 32 (16) 22 (11)
Calcium channel blockers, n (%) 26 (13) 27 (13)
aAnti-CCP, anticyclic citrullinated peptide; Anti-TNFα, anti–tumour necrosis
factor α; DAS28, Disease Activity Score in 28 joints; HAQ, Health Assessment
Questionnaire; NSAID, nonsteroidal anti-inflammatory drug; RA, rheumatoid
arthritis. bData were available for patients at baseline only. Extraarticular
manifestations include the presence of nodules, eye abnormalities, systemic
vasculitis, erosions, nailfold vasculitis, sicca, pulmonary fibrosis and serositis.
cCalculated in patients free of cardiovascular disease and cerebrovascular
disease. Results are expressed as median (25th to 75th percentile value),
number (%) or mean ± SD.
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All 201 patients successfully underwent assessments at
both time points. Table 1 displays the patient characte-
ristics. The majority of patients were females with mo-
derate to high disease activity at baseline, but relatively
lower disease activity during follow-up. The proportion
of patients with hypertension was similar between the
baseline and follow-up visits, whereas cases of dyslipi-
daemia were higher at the follow-up visits. The pro-
portion of patients with insulin resistance decreased
slightly at the follow-up visits, but the presence of dia-
betes increased. There were fewer current smokers at
the follow-up visits.
For medication use, the proportion of patients recei-
ving methotrexate or steroids was similar between the
two time points, whereas use of NSAIDs and COX2 in-
hibitors decreased at follow-up (see Table 1). There was
a marked increase in the proportion of patients receiving
anti-TNFα medications at follow-up compared to base-
line. The proportion of patients receiving antihyperten-
sives, β-blockers and calcium channel blockers remained
similar between the two time points. However, use of
antihypercholesterolaemics was significantly greater at
follow-up.
Baseline predictors of vascular outcomes in all
rheumatoid arthritis patients
The association between baseline factors and vascular out-
comes in 2012 is displayed in Additional file 1: Table S1a.
The presence of hypertension, dyslipidaemia and insulin
resistance all showed some association with reduced ACh
(P < 0.01). Hypertension and dyslipidaemia showed a simi-
lar relationship with SNP (P < 0.01). GTN was found to
have some association with both hypertension (P = 0.002)
and insulin resistance (P = 0.004), with the presence of
either factor resulting in a reduction in GTN. Hyper-
tension and insulin resistance were also found to be
associated with increased cIMT (P < 0.05). Neither the
ESR nor CRP values in 2006 showed any significant asso-
ciations with any of the 2012 outcomes considered. Dia-
betes was not shown to be associated significantly with
any of the outcomes.
Baseline predictors of vascular outcomes in rheumatoid
arthritis subgroups
As shown in Additional file 1: Table S1b, the results
for the patients in the RA subgroups who were free
of overt CVD and not taking COX2 inhibitors, NSAIDS
or anti-TNFα inhibitors (n = 104) are very similar to
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subgroups, insulin resistance was no longer associated
with ACh and GTN (P > 0.2). The P values for all sig-
nificant relationships were not as significant relative
to the analysis in all of the patients, but this result
was to be expected because the analysis was based on
only 50% of the sample size, which gives it less statis-
tical power.
Effect of smoking pack-years on cardiovascular disease
risk factors and vascular outcomes
The smoking pack-years in 2006 were compared to all
of the factors and outcomes in the analysis (Table 2).
From among all the factors, only insulin resistance wasTable 2 Relationship between smoking pack-years in
2006 and factors and outcomes in main analysisa
Factors in 2006 Smoking pack-years (2006)
Hypertension (2006) No (n = 69) 2 (0 to 18)
Yes (n = 132) 4 (0 to 19)
P-value 0.439
Dyslipidaemia (2006) No (n = 87) 2 (0 to 15)
Yes (n = 114) 3 (0 to 20)
P-value 0.774
Insulin resistance (2006) No (n = 127) 2 (0 to 15)
Yes (n = 65) 10 (0 to 26)
P-value 0.020b
Diabetes (2006) No (n = 194) 2 (0 to 18)
Yes (n = 7) 10 (0 to 35)
P-value 0.306
ESR (2006) Coefficient 0.073
P-value 0.301
CRP (2006) Coefficient 0.079
P-value 0.268
Ach (2012) Coefficient −0.141
P-value 0.050
SNP (2012) Coefficient −0.141
P-value 0.050
FMD (2012) Coefficient −0.074
P-value 0.313
GTN (2012) Coefficient −0.116
P-value 0.136
cIMT (2012) Coefficient 0.190
P-value 0.014b
aAch, acetylcholine; cIMT, carotid intima-media thickness; CRP, C-reactive
protein; ESR, erythrocyte sedimentation rate; FMD, flow-mediated dilatation; GTN,
glyceryl trinitrate–mediated dilatation; SNP, sodium nitroprusside. bSignificant at
P < 0.05. Data on hypertension, dyslipidaemia, insulin resistance and diabetes are
presented as median (25th to 75th quartiles), with P-values calculated using the
Mann–Whitney U test. Data on ESR, CRP, ACh, SNP, FMD, GTN and cIMT are
presented as Spearman’s correlation coefficient with associated P-values.significant, because patients with insulin resistance tended
to smoke significantly more than those without (P = 0.02).
For the outcomes, nonsignificant negative correlations
were found for all of the vascular parameters, other than
cIMT, which had a significant positive relationship with
pack-years (P = 0.01).
Cumulative inflammatory burden and vascular outcomes
The association of cumulative ESR and CRP with vascular
outcomes was examined using Spearman’s correlation.
This analysis revealed no evidence of any significant asso-
ciations between the AUCs of ESR and CRP with the vas-
cular outcomes (see Table 3). The only exception was a
weak but statistically significant correlation between the
AUC for CRP and the cIMT in 2012 (0.180; P = 0.034).
Discussion
The main findings of the present study are that classical
CVD risk factors, but not RA disease-related inflamma-
tion, predict microvascular endothelium-dependent
and endothelium-independent function, macrovascular
endothelium-independent function and carotid athero-
sclerosis in patients with RA who were prospectively
followed for six years. These findings were similar in a
subgroup of RA patients who were free from overt CVD
or were not taking NSAIDs, COX2 inhibitors or anti-
TNFα inhibitors, which suggests that the significant ef-
fects observed in the present study are generally inde-
pendent of the effects of heart disease and the three
medications that were considered. Furthermore, cumu-
lative inflammation was not associated with micro-
vascular and macrovascular endothelial function, but a
weak association was apparent between AUC for CRP
and carotid atherosclerosis.
It has previously been hypothesised that elevated inflam-
mation levels contribute to vascular impairments and sub-
sequent CVD risk in RA [3]. However, the present findings
after a long follow-up period suggest that inflammatory
levels at baseline are not associated with vascular function
and morphology. These findings are in agreement with




Vascular outcomes in 2012
ACh SNP FMD GTN cIMT
ESR Coefficient −0.079 −0.036 −0.053 −0.025 0.074
P-value 0.315 0.644 0.515 0.767 0.389
CRP Coefficient −0.114 −0.068 −0.027 0.007 0.180
P-value 0.114 0.384 0.732 0.936 0.034b
aAch, acetylcholine; AUC, area under the curve; cIMT, carotid intima-media
thickness; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FMD,
flow-mediated dilatation; GTN, glyceryl trinitrate–mediated dilatation; SNP,
sodium nitroprusside. bSignificant at P < 0.05.
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and the vasculature may be more apparent in patients with
high disease activity. Previous studies have shown that
patients with a high inflammatory burden at baseline ex-
perience greater improvement in vascular function when
treated with anti-inflammatory drugs than do patients
who have lower baseline inflammation [9,29]. The RA
patients in the present cohort had, on average, moderate
disease activity, and it is possible that baseline inflamma-
tion was not high enough to lead to vascular abnorma-
lities. It is also possible that assessing inflammation at a
single time point does not adequately reflect fluctuating
inflammation levels, which are characteristic of RA [10].
Therefore, we also calculated the cumulative inflamma-
tory burden and found a weak association of the AUCs
for CRP and cIMT.
To the best of our knowledge, there are no studies that
have assessed the impact of cumulative inflammation on
microvascular and macrovascular endothelial function to-
gether with assessments of carotid atherosclerosis in the
same group of RA patients. Previous studies have focused
mainly on vascular morphology and, similarly to the
present study, have reported associations with cumulative
inflammation [12,13,30]. In contrast to the present findings,
Vaudo and colleagues [11] reported associations between
cumulative inflammation and macrovascular endothelium-
dependent function. However, macrovascular endothelium-
dependent function in their study was considerably lower
than it was in the present study (3% vs. 11%, respectively)
and reflected a degree of endothelial dysfunction [8]. Given
that endothelial dysfunction is an inflammatory process,
an association between cumulative inflammation and
(depressed) macrovascular endothelium-dependent func-
tion could be much more likely in Vaudo and colleagues
patient population than in our cohort. Interestingly, stu-
dies which have assessed cumulative inflammation for the
whole duration of RA reported associations with the vas-
culature [13,30], whereas calculation of cumulative inflam-
mation for the most recent five years of RA did not [14].
In the current study, cumulative inflammatory burden was
calculated only for the six years during which the patients
were in the study, which may not reflect the true inflam-
matory burden. In addition, the increased use of biological
therapies, which may have a beneficial effect on CVD,
during the period these data were collected might have
resulted in lower inflammatory burden and may partly
explain our findings. Interestingly however, in our co-
hort, none of the vascular parameters differed between
patients receiving anti-TNFα inhibitor treatment com-
pared to those who did not.
In the microvasculature, the presence of hypertension, dys-
lipidaemia and insulin resistance at baseline predicted worse
microvascular endothelial function. In hypertension, the
delicate balance between vasodilators and vasoconstrictorsproduced by the endothelium is disrupted, with disturbance
in the NO pathway leading to predominance of vasocon-
strictors such as endothelin 1 (ET-1), which contribute to
high blood pressure [31]. Study investigators have reported
significant impairments in microvascular endothelium-
dependent function in hypertensive patients [32], and we
have previously shown that anti-inflammatory treatment
may reduce blood pressure in RA patients by improving
microvascular endothelium-dependent function [33]. Even
though it is still unclear whether endothelial dysfunction is
the cause or the consequence of elevated blood pressure, it
appears to be an essential factor in hypertension.
In the present cohort, dyslipidaemia was found to predict
microvascular endothelial function only. We have previ-
ously reported that improvements in microvascular
endothelium-dependent function, but not macrovascular
endothelium-dependent function, occur alongside a con-
comitant increase in high-density lipoprotein cholesterol in
RA [34]. This suggests that the microvessels may be more
susceptible to the adverse effects of dyslipidaemia. Indeed,
it has previously been hypothesised that the inflammatory
response initiated by hypercholesterolemia occurs in the
microvessels before the macrovessels [35]. In particular,
increased oxidative stress and elevated inflammatory
molecules within the vascular wall lead to a reduction in
NO bioavailability along with a concomitant reduction in
vasodilatation [5,35]. Intensive treatment with lipid-
lowering agents can lower CVD risk in RA [36], possibly
as a result of favourable effects in the vasculature.
Insulin resistance was also found to be associated with
worse microvascular endothelium-dependent function.
Patients with hyperglycaemia have evidence of micro-
vascular endothelial function, mainly due to oxidative
stress, as well as increased oxidation of low-density lipo-
protein cholesterol [37]. RA has been reported to have a
CVD risk burden and vascular profile similar to those of
diabetes [38], but diabetes was not shown to associate sig-
nificantly with any of the vascular outcomes in the present
study. However, the mean and median values do seem to
imply that RA patients with diabetes have poorer vascular
outcomes than those without it. The lack of statistical sig-
nificance is likely due to low statistical power, owing to the
fact that there were few RA patients with diabetes in this
cohort (<5% at baseline). Further prospective research
examining the effect of diabetes on vascular outcomes in a
large sample of RA patients is required.
In the macrovasculature, hypertension and insulin re-
sistance at baseline were both associated with macro-
vascular endothelium-independent function at follow-up.
These findings are similar to the results from our previous
cross-sectional study [9]. Assessments of macrovascular
endothelium-independent function reflect the integrity of
vascular smooth muscle cells [5]. Classical CVD risk
factors such as hypertension degrade cyclic guanosine
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sible for the relaxation of vascular smooth muscle cells. In
addition, in vitro studies have shown that soluble guanylyl
cyclase, an enzyme responsible for activating cGMP, has
reduced sensitivity to NO in hypertensive rats [40]. This
means that even if adequate NO is released from the endo-
thelial cells, abnormalities in smooth muscle cell signalling
could still lead to a reduced vasodilatory response.
Similarly to macrovascular endothelium-independent
function, RA patients with hypertension and insulin resist-
ance at baseline exhibited greater carotid atherosclerosis
at follow-up than patients without these risk factors.
Changes in cIMT represent a sequence of events resulting
from a decrease in NO bioavailability as well as an in-
crease in ET-1 levels, which over time lead to increased
production of proinflammatory cytokines, leucocyte adhe-
sion, activation of thrombotic factors, proliferation of vas-
cular smooth muscle cells and formation of lipid-rich
plaques [5]. A previous study of a small number of RA pa-
tients (N = 47) revealed that patients who experienced a
cardiac event during a five-year follow-up period had
higher cIMT at baseline than patients who did not have a
cardiac event [41]. These findings, together with our
current findings, suggest that classical CVD risk factors in-
crease carotid atherosclerosis, which might then result in
a higher risk for cardiac events. Indeed, it has recently
been shown that cIMT is more sensitive than coronary ar-
tery calcification for identifying RA patients at high risk
for CVD [42].
In the present study, we also examined the relationship
of smoking pack-years with other CVD risk factors and
vascular outcomes. RA patients with insulin resistance
smoked more than those without insulin resistance. Fur-
thermore, higher smoking pack-years were associated with
greater carotid atherosclerosis. Relating this finding back
to the original analysis, the significance of the relationship
between insulin resistance and carotid atherosclerosis
could have been due in part to the effect of smoking. This
is because patients with insulin resistance smoke more fre-
quently, and more frequent smokers have higher cIMT.
Hence, one would expect the patients with insulin resist-
ance to have higher cIMT due to the effect of smoking.
The strengths of the present study are the inclusion of a
large sample of RA survivors from the DRACCO study
who were prospectively followed for a long period, as well
as the incorporation of several assessments of vascular
function and morphology in the microvasculature and the
macrovasculature. Such a study design allowed us to
investigate specific predictors of vascular outcomes over a
protracted time period and provide important additional
information on CVD risk. The calculation of cumulative
inflammatory burden allowed for the natural fluctuations
in disease activity to be taken into account when examin-
ing associations with vascular outcomes. However, alimitation of the study is that cumulative inflammation
was calculated only for the duration of the study. There is
a possibility that inflammation might have been higher
early in the patient’s disease course, when optimum treat-
ment had not yet been achieved. Consequently, the calcu-
lation of cumulative inflammation in the present study
may have underestimated the total inflammatory load of
the patient. Unfortunately, the current study assessed only
survivors, and several patients experienced cardiovascular
events in the observation period but were not included in
the analysis. It is possible that different factors might affect
vascular function and morphology in such patients. Never-
theless, the findings of the present study suggest that care-
ful screening of CVD risk should include assessment of
vascular function and morphology and that such assess-
ments should be used as outcome measures in interven-
tions that aim to reduce CVD risk [43].
We focused on the impact of inflammation and classical
CVD risk factors on the vasculature. However, a recently
published study in a large RA cohort revealed that several
other factors, such as genes (for example, HLA-DRB1
shared epitope alleles), RA-specific factors (for example,
autoantibodies and use of systemic steroids) and other fac-
tors such as hypothyroidism predicted the presence of
CVD in RA [44,45]. Further studies are required to assess
the impact of nontraditional CVD risk factors on vascular
function and morphology in RA. The findings of the
present study specifically highlight the importance of con-
trolling disease activity and classical CVD risk factors in
order to halt the progression of vascular abnormalities.
Conclusion
The present study reveals that classical CVD risk factors
may be better long-term predictors of vascular function
and morphology than systemic disease-related inflamma-
tion in patients with RA. Further studies are needed to
confirm whether assessments of vascular function and
morphology are predictive of long-term CV outcomes in
RA patients.
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